SCHEMBL25015538

SCHEMBL25015538

COC(=O)c1cc(-c2c[nH]cc2C(=O)OCc2ccccc2)cn1S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 1/20 0.57
▸ OPRD1 P41143 1/20 0.57
▸ MAPT P10636 2/20 0.42
▸ LMNA P02545 2/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ TRIM24 O15164 1/20 0.38
▸ TRIM33 Q9UPN9 1/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ SLC1A3 P43003 1/20 0.37
▸ SLC1A2 P43004 1/20 0.37
▸ SLC1A1 P43005 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ CA1 P00915 2/20 0.37
▸ CA2 P00918 2/20 0.37
▸ ALOX5 P09917 1/20 0.37
▸ DHODH Q02127 1/20 0.37
▸ FOLH1 Q04609 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20816040 0.92 OPRM1 (0.48) OPRM1OPRD1MAPTLMNAL3MBTL1
SCHEMBL20816043 0.91 OPRM1 (0.47) OPRM1OPRD1MAPTLMNAL3MBTL1
SCHEMBL23484064 0.86 OPRM1 (0.41) OPRM1OPRD1LMNAL3MBTL1MEN1
SCHEMBL6828215 0.78 MAPT (0.51) OPRM1OPRD1MAPTLMNAL3MBTL1
SCHEMBL6828202 0.78 MAPT (0.46) OPRM1OPRD1MAPTLMNAL3MBTL1
SCHEMBL6828206 0.76 MAPT (0.47) OPRM1OPRD1MAPTLMNAL3MBTL1
SCHEMBL6828344 0.76 MAPT (0.44) OPRM1OPRD1MAPTLMNAL3MBTL1
SCHEMBL2117466 0.76 MAPT (0.50) OPRM1OPRD1MAPTLMNAL3MBTL1
SCHEMBL6828214 0.73 MGLL (0.46) OPRM1OPRD1MAPT
SCHEMBL23483863 0.72 OPRM1 (1.00) OPRM1OPRD1MAPTLMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230044407-A1 TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER THE TRUSTEES OF DARTMOUTH COLLEGE 2023-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230044407-A1 TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER MYCBP, MYC, TERF2IP OPRM1 3570/4885OPRD1 3669/4885MAPT 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback